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Abstract
Background: Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH)
and chronic thromboembolic pulmonary hypertension (CTPEH). The objective of this study was to evaluate right heart
size and function assessed by echocardiography during long term treatment with riociguat.
Methods: Patients who started riociguat treatment (1.0–2.5 mg tid) within the trials phase II, PATENT, PATENTplus, EAS,
CHEST and continued treatment for 3–12months were included in this study. Echocardiography was analysed off-line
at baseline, after 3, 6 and 12months by investigators who were blinded to clinical data. Last and baseline observation
carried forward method (LOCF, BOCF) were performed as sensitivity analysis.
Results: Seventy-one patients (45% PAH, 55% CTEPH; 53.5% female; 60 ± 13 years, mean pulmonary arterial pressure
46 ± 10mmHg, mean PVR 700 ± 282dynes·sec·cm-5) were included. After 6months, RA and RV area, RV thickness tricuspid
regurgitation velocity showed a significant reduction. After 12 months, patients receiving riociguat therapy
showed a significant reduction in right atrial (− 2.6 ± 4.4 cm2, 95% CI -3.84, − 1.33; p < 0.001, n = 49) and right
ventricular (RV) area (− 3.5 ± 5.2 cm2, 95% CI -5.1, − 1.9; p < 0.001; n = 44), RV thickness (− 0.76 ± 2.2mm, 95% CI -1.55, 0.03;
n= 32), and a significant increase in TAPSE (2.95 ± 4.78 mm, 95% CI 1.52, 4.39; n = 45) and RV fractional area
change (8.12 ± 8.87 mm, 95% CI 4.61, 11.62; n = 27).
Both LOCF and BOCF showed similar results but lower effect sizes.
Conclusion: Patients under long-term treatment with riociguat show significantly reduced right heart size
and improved RV function in PAH and CTEPH. Further controlled prospective studies are needed to confirm
these results.
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Background
Pulmonary arterial hypertension (PAH) and chronic
thromboembolic pulmonary hypertension (CTEPH) are
conditions both characterized by a progressive vascular
remodeling, increase in pulmonary arterial pressure, pul-
monary vascular resistance (PVR) and right ventricular
(RV) overload that can ultimately lead to right heart fail-
ure and death [1]. At diagnosis most patients show an
enlarged right heart with increased RV and right atrial
(RA) area (>16cm2) and impaired cardiac output (CO).
Riociguat is the first drug that has been approved for the
treatment of both PAH and CTEPH [2, 3]. In patients
with PAH, the 12-week PATENT-1 study showed a signifi-
cant improvement of the primary endpoint 6-min walking
distance (6MWD) and of secondary end-points as PVR,
N-terminal prohormone brain natriuretic peptide (NT-
proBNP) levels, World Health Organisation functional
class (WHO-FC), time to clinical worsening, and Borg
dyspnea score [2]. An exploratory analysis of the first 12
weeks of the long-term extension study (PATENT-2)
showed further significant improvement of 6-MWD in the
215 PAH-patients receiving up to 2.5mg of riociguat three
times daily [4].
In CTEPH patients the 12-week CHEST-1 study revealed
a statistically significant improvement of 6MWD (primary
end-point) and in PVR, NT-proBNP serum values, and in
WHO-FC (secondary end points) [3]. Further studies inves-
tigating the effect of riociguat in an uncontrolled design
were the early access study (EAS) in patients with CTEPH
[5] and PATENTplus in PAH [1]. Due to potentially un-
favourable safety signals with sildenafil plus riociguat in
the PATENTplus study and no evidence of a positive
benefit/risk ratio, concomitant use of riociguat with
phosphodiesterase-5 inhibitors is contraindicated [6].
Sparse data are currently available on the effects of rio-
ciguat administration on right heart size and function. RV
size and function have not been addressed as end-points in
the respective riociguat studies. The study protocols of the
phase III riociguat studies did not include echocardio-
graphic assessments to investigate right heart size as RV or
RA areas. However, right heart size and function are of
utmost prognostic importance in PAH/CTEPH. RV per-
formance measured by echocardiography [7, 8] and en-
larged RA area [7, 9] have been shown to be independent
prognostic factors in PAH. Recently it has been shown that
riociguat treatment (1.0–2.5mg tid) was associated with a
significant reduction of RV and RA area after 3, 6 and 12
months compared to baseline [10]. RA area significantly de-
creased after 12months and RV systolic function assessed
with tricuspid annular plane systolic excursion (TAPSE) im-
proved after 6 and 12months of riociguat therapy [10].
The aim of the current study was to assess the effects
of long-term riociguat treatment on right heart size and
function measured by echocardiography in patients with
PAH or CTEPH who have been enrolled in the prospect-
ive, randomized, double-blind, multicentre, parallel-group,
placebo-controlled riociguat trails PATENT-1, PATENT-
plus, CHEST-1, phase II trial and Early Access Study and
the corresponding long-term extension trials.
Methods
Study design
This clinical investigation was performed as a retrospective
analysis using the data of prospective, randomized, double-
blind, multicentre, parallel-group, placebo-controlled clinical
studies (riociguat trails PATENT-1 study, PATENTplus
study, CHEST-1 study, phase II trial and Early Access Study)
and the corresponding long-term extension trials with add-
on of echocardiographic data obtained during routine as-
sessments which have been performed during these trials.
All riociguat studies were approved by the ethics commit-
tees of the respective centers. The ethics committee of the
medical faculty, University of Heidelberg had no objection
against the retrospective analysis of echocardiographic data
within this study (S668–2015). Due to the small number of
patients with available echocardiographic data receiving pla-
cebo, the data was evaluated as single armed, observational
study.
Study population
German centres were contacted to include patients
who were enrolled within the riociguat phase II and III
trials and received routine echocardiographic assess-
ments throughout the study period. In five centres
Dresden, Hannover, Heidelberg, Giessen and Regensburg
echocardiographic assessments were routinely performed
at baseline and after 3, 6 and 12months beside the param-
eters which have been obtained in the context of the rioci-
guat trials. All patients with PAH (PATENT-1 and 2,
PATENTplus) or CTEPH (CHEST-1 and 2, Early Access
Study) randomized into one of the trials (i.e. for whom
study medication had been assigned and a package had
been opened) and who had at least once been adminis-
tered study medication were eligible for the study, if echo-
cardiography had been routinely performed at baseline
and at least once during the course of the trial.
Analysis of echocardiography
For analysis of the echocardiographic parameters includ-
ing RA and RV areas, TAPSE, RV thickness, tricuspid
regurgitation velocity, RV fractional area change, right
and left ventricular systolic function, left ventricular eccen-
tricity index, pulmonary artery diameter and presence of
pericardial effusion we obtained the DICOM-films of the
on-line echocardiographic assessments performed in each
centre and analysed them off-line in Heidelberg. In case of
low image quality and lacking multiple measurements,
values were not included in the data base. For the off-line
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readings specialised software was used (TOMTEC) by an
experienced physician. The investigator (AM) who per-
formed the off-line readings of the echocardiography-
DICOM-data was blinded to the patient name, treatment
group, location and time point of the assessment, demo-
graphic and clinical data. All echocardiographic measure-
ments were performed according to American Society of
Echocardiography/European Association of Cardiovascular
imaging guidelines [11]. Accordingly, RA area and RV area
were measured at the end of ventricular diastole (largest
volume), tracing following the endocardium from the
lateral aspect of the tricuspid annulus to the septal aspect,
excluding the area of the annulus and the leaflets (with
regard to RA area) and excluding the area of the annulus
and trabecular structures (with regard to RV area). RV
systolic area was calculated with the same methodology
but at the end of the systole. RV fractional area change
was defined as: [(RV end-diastolic area – RV end-sys-
tolic area)/ RV diastolic area]*100. TAPSE was calcu-
lated using M-mode from the lateral tricuspid annulus.
Results of off-line readings were forwarded to an exter-
nal contract research organisation in order to merge
with the clinical data of the riociguat trials. A clinically
significant improvement of right heart size was defined
as a ≥ 15% reduction RA or RV area [12].
Data collection
Data from the riociguat studies were used for this study to
complete clinical characterization of the patient cohort. The
respective parameters from the riociguat trials database were
merged with the echocardiography data after double pseu-
donymization for data protection by contract research or-
ganisation. Parameters comprised of baseline demographics,
vital signs, WHO functional class, hemodynamics, 6-min
walking distance, NTpro-BNP and PH targeted treatment.
Patients who received riociguat in the core study were
included with their baseline examination of the core study
and the subsequent follow-up examinations. Patients who
received placebo in the core study and riociguat in the ex-
tension study were included with their final examination of
the double-blind study (= baseline examination of the ex-
tension study) and the subsequent follow-up examinations.
Patients with invalid echocardiographic recordings, in-
sufficient quality of recordings or missing baseline echo-
cardiography were excluded from the analysis.
Statistics
Descriptive statistics are displayed by mean ± standard
deviation, median and interquartile ranges. Frequency
tables are provided for qualitative data. The primary
endpoint was defined as the change of RA area from
baseline to 12months of treatment. The second part of
the primary endpoint with comparison of changes dur-
ing treatment between riociguat and placebo group was
not possible due to the small sample size of the placebo
group (n = 5). Previous power analysis for the primary
endpoint determined a statistical power of at least 87.7%
at an alpha level of 0.025 with a sample size of 75 pa-
tients if the true treatment effect was a reduction of RA
area of at least 3 cm2 with a standard deviation of the
difference of 7.5 cm2 after 12 months of treatment.
For the comparison of baseline and follow up values
the t-test for paired measurements or the Wilcoxon
signed rank test was used, as appropriate. Frequency dis-
tributions between baseline and follow-up were com-
pared with the test of marginal homogeneity if at least
one of the variables had more than two different values.
For 2 × 2 tables the McNemar test was performed. Com-
parisons between groups were analysed with the t-test
for independent samples or the Mann Whitney U test.
For the comparison of frequency distributions between
groups Fishers exact test was used.
For missing values of echocardiographic parameters after
12months, baseline observation carried forward (BOCF)
and last observation carried forward (LOCF) methods were
performed as sensitivity analysis.
All tests are two-tailed and p-values < 0.05 were con-
sidered as statistically significant. All analyses were per-
formed with SAS 9.3 for Windows (SAS Institute, Cary
NC) and SPSS V 24.
Results
Within the riociguat studies the participating centres
included 112 patients (55% female, 43% PAH, 60 ± 13
years; 20 patients starting with placebo, 92 with rioci-
guat), who had at least one echocardiographic assess-
ment during the treatment period. In 71 patients (54%
female, 83% treatment-naïve, 60 ± 13 years, mean pul-
monary arterial pressure 46 ± 10 mmHg; Table 1, Fig. 1)
echocardiography was available at the start date of the
riociguat treatment. Out of them, 59 started the study
with riociguat (83.1% of 71), 12 with placebo (16.9% of
71); the latter were switched to open-label riociguat
after 12 and 16 weeks, respectively. In 20 patients who
received initial placebo treatment, data from baseline
echocardiography was available. Out of them, five pa-
tients presented with echocardiographic data after 3
months of placebo treatment. Because of the small and
possibly biased placebo group, we did not perform a
statistical test for the comparison of both groups.
No patient died throughout the reported study period.
Two patients who were not included in the analysis (due
to missing echocardiographic assessment) received a
lung transplantation.
Effect of riociguat on right heart size and function
Imaging quality was very good in > 90% of cases. In 71
patients with baseline-echocardiography, changes of
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echocardiographic parameters after three (n = 30), six
(n = 34) and 12 months (n = 50) are shown in Table 2.
Patients receiving riociguat therapy showed a significant re-
duction in RA area after 6 (− 2.4 ± 3.7 cm2, 95% confidence
interval (CI) -3.73, − 1.13; p < 0.001, n = 34) and 12months
(− 2.6 ± 4.4 cm2, 95% CI -3.84, − 1.33; p < 0.001, n = 49).
Likewise, patients showed a significant decrease in RV
area (3 months: − 3.0 ± 3.0 cm2, 95% CI -4.1, − 1.9; 6
months:− 3.0 ± 3.15 cm2, 95% CI -4.23, − 1.96; 12
months: − 3.5 ± 5.2 cm2, 95% CI -5.1, − 1.9; p < 0.001 for
all time points; n = 29, 32, 44, respectively). Patients
who completed all four echocardiographic assessments
(at baseline, after 3, 6 and 12 months (n = 21)) pre-
sented with a significant reduction of RA and RV areas
for all time points (Table 2, Fig. 2).
After three months seven of 30 patients had a marked re-
duction in RA area of ≥15% compared to baseline (23.3% of
30); after six months 14 patients reached this reduction
(41.2% of 34) and after 12months 23 patients (46.9% of 49)
(Table 2).
Table 1 Baseline characteristics of the study cohort
Mean ± standard
deviation or n and (%)
95% CI (mean) median and
interquartile
ranges
Variable N lower limit upper limit
Demographics
Age [years] 71 59.1 ± 13.42 56.0 62.3 60 [50; 71]
Height [cm] 71 167.6 ± 9.89 165.2 169.9 168 [160; 174]
Weight [kg] 71 76.91 ± 17.53 72.77 81.06 73.0 [65; 87]
BMI [kg/m2] 71 27.26 ± 5.04 26.06 28.45 26.42 [24; 29.05]
gender [female n (%)] 38 (53.5%)
Pulmonary hypertension etiology
Idiopathic PAH 14 (19.7%)
CTD-APAH 10 (14.1%)
Other PAH 8 (11.3%)
Chronic thromboembolic pulmonary hypertension 39 (54.9%)
WHO functional class
II 17 (23.9%)
III 54 (76.1%)
Pulmonary hypertension targeted treatment
treatment naÏve 52 (73%)
Endothelin-Receptor-Antagonist 14 (20%)
Phosphodiesterase-5-inhibitor 5 (7%)
Oxygen 7 (10%)
Vital signs
Systolic Blood Pressure [mmHg] 71 114.3 ± 12.90 111.2 117.3 110 [105; 123]
Diastolic Blood Pressure [mmHg] 71 72.0 ± 9.93 69.6 74.3 70 [65; 80]
Heart Rate [bpm] 71 80.6 ± 9.99 78.2 83.0 80 [72; 88]
Clinical parameters
NTproBNP [pmol/L] 41 140.97 ± 230.87 68.10 213.84 43.3 [18.1; 175.5]
6-min walking distance [meters] 68 359.0 ± 91.48 336.9 381.1 359 [295; 419]
Hemodynamics measured by right heart catheter
mean PAP [mmHg] 45 46.13 ± 9.833 43.17 49.08 46.0 [39; 54]
Pulmonary Vascular Resistance [dyn*sec*cm−5] 45 700.75 ± 282.82 615.79 785.72 593.6 [510.6; 829]
Cardiac Index [L/min/m2] 45 2.53 ± 0.46 2.39 2.66 2.58 [2.31; 2.78]
Cardiac Output [L/min] 45 4.69 ± 1.06 4.37 5.01 4.6 [4.3; 5.2]
Pulmonary Arterial Wedge Pressure [mmHg] 45 7.4 ± 2.85 6.5 8.2 7 [5; 8]
CI confidence interval, BMI Body mass index, PAH pulmonary arterial hypertension, CTD connective tissue disease
NTproBNP fragment of N-terminal pro brain natriuretic peptide, PAP pulmonary arterial pressure
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At baseline 20 of 70 patients showed a RA area lower
than 18cm2 (28.6% of 70, one patient with baseline echo-
cardiography had a missing RA area value). After 3
months 15 had a RA area < 18 cm2 (50.0% of 30), after 6
months 18 (52.9% of 34) and after 12 months 25 (51.0%
of 49), respectively (Table 2).
After 12months of riociguat treatment patients showed
a significant decrease in RV thickness (− 0.76 ± 2.2 mm,
95% CI -1.55, 0.03), tricuspid regurgitation velocity
(− 0.36 ± 0.83 cm/sec, 95% CI -0.6, − 0.12), pulmonary
artery diameter (− 1.64 ± 3.17mm, 95% CI -2.92, 0.36) and
a significant increase in TAPSE (2.95 ± 4.78mm, 95% CI
1.52, 4.39) and RV fractional area change (8.12 ± 8.87mm,
95% CI 4.61, 11.62) (Table 2).
Patients also presented with an improvement of quali-
tatively assessed RV systolic function after 12 months of
treatment (normal systolic function at baseline n = 6 vs.
16 at 12 months, mild impairment 15 vs. 16, moderate
impairment 15 vs. 7, severe impairment 9 vs. 6; χ2-test
p = 0.016). Left ventricular systolic function and pres-
ence of pericardial effusion remained stable throughout
the study period. Both LOCF and BOCF showed similar
significance and lower effect sizes (data not shown).
After 12months of riociguat treatment patients showed
a significant increase in mean 6MWD (59.6 ± 81 m,
p < 0.001).
Description of patients who did not receive
echocardiography after 12months
Echocardiography after 12 months riociguat treatment
was performed for 50 out of the 71 riociguat patients
with echocardiography at riociguat start (70.4% of 71),
21 patients had no echocardiography after 12 months
(29.6% of 71).
Patients who did not complete their 12-month echocar-
diographic assessment did not significantly differ regarding
gender, age, height, weight, severity of the disease, 6MWD
and hemodynamics from patients who received an echocar-
diographic examination after 12months (Table 3, all p >
0.05). Baseline values for 6MWD and cardiac index were
lower, pulmonary vascular resistance and NT-proBNP
higher in patients who did not complete their 12month
examination, though differences between the two groups
did not reach statistical significance (Table 3). Median
values for PVR, cardiac index and cardiac output were simi-
lar between groups.
Patients with 12-month assessment showed a statisti-
cally significant but clinically not relevant lower diastolic
blood pressure and higher PAWP (Table 3).
Placebo group
In 20 patients who received placebo treatment, data from
baseline echocardiography was available. Out of them, five
patients presented with echocardiographic data after 3
months. Patients who received placebo treatment had a
mild increase in NT-proBNP (22 ± 104 pmol/l) and
6MWD (18 ± 55 m).
Due to the small sample size of five patients who re-
ceived an echocardiographic assessment after 3 months,
the effect of riociguat was not tested for statistical sig-
nificance against the control group. Data of patients re-
ceiving placebo treatment are presented descriptively
Fig. 1 RIVER study Flow-Chart. All patients with PAH (PATENT-1 and 2, PATENTplus) or CTEPH (CHEST-1 and 2, Early Access Study) randomized
into one of the trials (i.e. for whom study medication had been assigned and a package had been opened) and who had at least once been
administered study medication were eligible for the study, if echocardiography had been routinely performed at baseline and at least once
during the course of the trial
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(Table 4). RA area slightly decreased within 3months
(0.4 ± 2.9), whereas RV area increased by 1.9 ± 6.4 cm2.
During the three month period, an increase was seen in
TAPSE (0.5 ± 3.2 mm) and RV thickness (1 ± 0.8 mm).
Median values of differences between baseline and 3
months did not reveal any marked changes. Presence of
pericardial effusion and RV function also remained con-
stant within the 3 months study period.
Discussion
To the best of our knowledge this is the first multicentre
study showing a reduction of right heart size and im-
provement of right heart function during treatment with
riociguat in patients with PAH or CTEPH. After 6 and
12months of riociguat treatment, RV and RA area
assessed by echocardiography decreased. At the same
time, RV systolic function and RV hypertrophy im-
proved. These results were obtained by blinded off-line
readings of echocardiographic assessments which have
been performed within riociguat trials.
Relevance of right heart size and function in pulmonary
hypertension
These data confirm the results of a recent unblinded
single-center study [10] which showed a significant
improvement of right ventricular area already after 3
months, an improvement of RV systolic function after 6
months and right atrial area after 12 months treatment.
In the current study, RA area was already significantly
improved after 6 months of riociguat treatment.
As the current guidelines on treatment goals in pulmon-
ary hypertension state, RA area seems to be one of the
most robust echocardiographic determinants of outcome
[13] and strongly correlates with RV function [9]. Enlarged
RA assessed by transthoracic echocardiography was signifi-
cantly associated with lower transplant-free survival [7, 14]
whereas RA area < 18 cm2 was associated with a good prog-
nosis [9, 14]. In this study a reduction of RA area ≥ 15%
was achieved by almost 50% of the patients. It has been
shown previously that a therapy response to PH targeted
medication of ≥15% in RA and RV area may predict
long-term outcome in patients with PH [12]. Using the pro-
posed cut-off for a normal RA area of 15cm2 in female and
16 cm2 in males [15], 31% of patients who presented with
baseline values above these cut-offs showed values within
the normal ranges after one year of riociguat treatment.
A reduction of right heart size might be an indicator
for an improvement of systolic function and reduction
in volume overload. In this study the reduction of right
heart size was accompanied by a significant improve-
ment of RV systolic function assessed by RV fractional
area change, TAPSE and qualitative assessment of RV
systolic function.
Preclinical studies showed that Riociguat has a positive
effect on pulmonary pressures [16], and is able to re-
verse RV remodeling [17]. In our study, riociguat admin-
istration was associated with an improvement of both
RV systolic function, as well as of pulmonary pressures
(TRV). The investigation of the underlying predominant
mechanisms of riociguat treatment was however out of
the scope of our study.
Fig. 2 Right atrial and right ventricular areas in patients who completed all four echocardiographic assessments. Patients who completed
echocardiographic assessments at baseline, 3, 6 and 12months showed a significant reduction of right atrial and right ventricular areas for all
time points. Values are given as mean ± standard error of the mean
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Strengths and limitations
A strength of this study is the central off-line reading of
echocardiographic data by a blinded experienced physician
which standardized the interpretation of data and increases
its quality. In addition, patients included in this analysis
were enrolled in prospective randomized controlled rioci-
guat trials, leading to a thorough and homogenous patient
selection (due to similar in- and exclusion criteria of the
trials) and high quality of clinical data. As the echocar-
diographic data derived from routine echocardiographic
assessments and were assessed according to the local
standards of the participating centres, the study results
represent data from clinical practice.
On the other hand, the rate of patients who did not
receive echocardiographic assessments after 12months
may have biased the results. However, sensitivity analyses
of echocardiographic parameters after 12months with
BOCF and LOCF led to similar significant results with
lower effect sizes (data not shown).
Further study limitations are the retrospective nature of
the study, limited number of study centres and a small
number of patients, in particular those receiving placebo
treatment. A higher number of patients receiving riociguat
would also have been desirable in order to compare the
effects on patients with PAH vs. CTEPH.
Conclusion
This study suggests that treatment with riociguat may
improve right heart function in patients with PAH and
CTEPH within 12 months of treatment. Prospective,
controlled studies are needed to confirm the effects of
riociguat on right heart size and function in these
patients.
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